These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24281222)

  • 1. Assessment of factors associated with dose differences between Japan and the United States.
    Arnold FL; Fukunaga S; Kusama M; Matsuki N; Ono S
    Clin Pharmacol Ther; 2014 May; 95(5):542-9. PubMed ID: 24281222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approaches to Japanese dose evaluation in global drug development: factors that generate different dosages between Japan and the United States.
    Nakashima K; Narukawa M; Takeuchi M
    Clin Pharmacol Ther; 2011 Dec; 90(6):836-43. PubMed ID: 22048222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences between Japan and the United States in dosages of drugs recently approved in Japan.
    Nakashima K; Narukawa M; Kanazu Y; Takeuchi M
    J Clin Pharmacol; 2011 Apr; 51(4):549-60. PubMed ID: 20628171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring differences in drug doses between Japan and Western countries.
    Arnold FL; Kusama M; Ono S
    Clin Pharmacol Ther; 2010 Jun; 87(6):714-20. PubMed ID: 20410879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significant differences in drug lag in clinical development among various strategies used for regulatory submissions in Japan.
    Ueno T; Asahina Y; Tanaka A; Yamada H; Nakamura M; Uyama Y
    Clin Pharmacol Ther; 2014 May; 95(5):533-41. PubMed ID: 24213186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically based pharmacokinetic modeling: from regulatory science to regulatory policy.
    Sinha V; Zhao P; Huang SM; Zineh I
    Clin Pharmacol Ther; 2014 May; 95(5):478-80. PubMed ID: 24747236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delays in new drug applications in Japan and industrial R&D strategies.
    Hirai Y; Kinoshita H; Kusama M; Yasuda K; Sugiyama Y; Ono S
    Clin Pharmacol Ther; 2010 Feb; 87(2):212-8. PubMed ID: 19940847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Same drug, different dosing: differences in dosing for drugs approved in the United States, Europe, and Japan.
    Malinowski HJ; Westelinck A; Sato J; Ong T
    J Clin Pharmacol; 2008 Aug; 48(8):900-8. PubMed ID: 18524997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI
    Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with spontaneous reporting of adverse drug reactions in Japan.
    Yamada T; Watanabe Y; Kusama M; Sugiyama Y; Ono S
    Pharmacoepidemiol Drug Saf; 2013 May; 22(5):468-76. PubMed ID: 23172714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of regulatory review times of new drugs in Japan: association with characteristics of new drug applications, regulatory agency, and pharmaceutical companies.
    Ishibashi T; Kusama M; Sugiyama Y; Ono S
    J Clin Pharm Ther; 2012 Dec; 37(6):657-63. PubMed ID: 22734557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteriation of clinical data packages using foreign data in new drug applications in Japan.
    Tanaka M; Nagata T
    Clin Pharmacol Ther; 2008 Sep; 84(3):340-6. PubMed ID: 17786162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of labeling decisions regarding therapeutic indications during new drug application reviews in Japan.
    Yokota M; Kusama M; Sugiyama Y; Ono S
    Clin Pharmacol Ther; 2011 Sep; 90(3):432-41. PubMed ID: 21814198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of the relationship between a starting dose in first-in-human studies and no observed adverse effect level in nonclinical studies.
    Sato A; Narukawa M
    Int J Clin Pharmacol Ther; 2014 Sep; 52(9):770-6. PubMed ID: 25034619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive review of the pharmacokinetics of approved therapeutic monoclonal antibodies in Japan: Are Japanese phase I studies still needed?
    Chiba K; Yoshitsugu H; Kyosaka Y; Iida S; Yoneyama K; Tanigawa T; Fukushima T; Hiraoka M
    J Clin Pharmacol; 2014 May; 54(5):483-94. PubMed ID: 24242979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statistical concepts in the planning and evaluation of drug safety from clinical trials in drug development: issues of international harmonization.
    O'Neill RT
    Stat Med; 1995 May 15-30; 14(9-10):117-27. PubMed ID: 7569506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer drug development from traditional cytotoxic to targeted therapies: evidence of shorter drug research and development time, and shorter drug lag in Japan.
    Kawabata-Shoda E; Masuda S; Kimura H
    J Clin Pharm Ther; 2012 Oct; 37(5):547-52. PubMed ID: 22428857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gatekeepers and enablers: how drug regulators respond to a challenging and changing environment by moving toward a proactive attitude.
    Ehmann F; Papaluca Amati M; Salmonson T; Posch M; Vamvakas S; Hemmings R; Eichler HG; Schneider CK
    Clin Pharmacol Ther; 2013 May; 93(5):425-32. PubMed ID: 23549149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploratory Analysis of Associations Between Postmarketing Safety Events and Approved Doses of New Drugs in Japan.
    Okubo TK; Ono S
    Clin Transl Sci; 2017 Jul; 10(4):280-286. PubMed ID: 28371388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Drug Characteristics for Implementing Multiregional Clinical Trials Including Japan.
    Rokuda M; Matsumaru N; Tsukamoto K
    Clin Ther; 2018 Feb; 40(2):284-295. PubMed ID: 29361305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.